Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$17.69
-0.52-2.86%
At close: Jun 18, 5:00 PM EST
$17.69
N/A
After Hours: 4:24 PM EST
Crescent Biopharma Inc Analyst Ratings
CBIONASDAQ
Crescent Biopharma Analyst Ratings and Price Targets | NASDAQ:CBIO | Benzinga
Crescent Biopharma Inc has a consensus price target of $27.6 based on the ratings of 6 analysts. The high is $35 issued by Guggenheim on January 21, 2026. The low is $22 issued by LifeSci Capital on June 18, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Guggenheim, and HC Wainwright & Co. on March 2, 2026, January 21, 2026, and August 27, 2025, respectively. With an average price target of $27.33 between HC Wainwright & Co., Guggenheim, and HC Wainwright & Co., there's an implied 54.51% upside for Crescent Biopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Jefferies
Wedbush
Stifel
LifeSci Capital
1calculated from analyst ratings
Analyst Ratings for Crescent Biopharma
Loading calendar...
FAQ
What is the target price for Crescent Biopharma (CBIO) stock?
The latest price target for Crescent Biopharma (NASDAQ:CBIO) was reported by HC Wainwright & Co. on June 1, 2026. The analyst firm set a price target for $0.00 expecting CBIO to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Crescent Biopharma (CBIO)?
The latest analyst rating for Crescent Biopharma (NASDAQ:CBIO) was provided by HC Wainwright & Co., and Crescent Biopharma downgraded their neutral rating.
When was the last upgrade for Crescent Biopharma (CBIO)?
There is no last upgrade for Crescent Biopharma
When was the last downgrade for Crescent Biopharma (CBIO)?
The last downgrade for Crescent Biopharma Inc happened on June 1, 2026 when HC Wainwright & Co. changed their price target from N/A to N/A for Crescent Biopharma Inc.
When is the next analyst rating going to be posted or updated for Crescent Biopharma (CBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crescent Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crescent Biopharma was filed on June 1, 2026 so you should expect the next rating to be made available sometime around June 1, 2027.
Is the Analyst Rating Crescent Biopharma (CBIO) correct?
While ratings are subjective and will change, the latest Crescent Biopharma (CBIO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Crescent Biopharma (CBIO) is trading at is $17.69, which is out of the analyst’s predicted range.
